You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Colorectal cancer

Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer

  • Technology appraisal guidance
  • Reference number: TA212
  • Published:  15 December 2010
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Colorectal cancer (metastatic) - bevacizumab: final appraisal determination

Colorectal cancer (metastatic) - bevacizumab: final appraisal determination Colorectal cancer (metastatic) - bevacizumab: final appraisal determination
12 November 2010
(236.85 Kb 8 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 09 November 2010

Back to top